Shares of biotech company Geron (NASDAQ: GERN) dropped more than 20% today after it announced the cancellation of its GRN1005 cancer drug program. The drug's poor interim results have led the company to refocus its strategy on developing another drug, called imetelstat. Investors can't be happy about today's news, as shares of Geron were already halved in September following poor results from two of imetelstat's four clinical trials.
In the following video, health care analysts Max Macaluso and Brenton Flynn discuss this news and review the company's latest changes.
